These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 24565163)

  • 21. Kidney-on-a-Chip: A New Technology for Predicting Drug Efficacy, Interactions, and Drug-induced Nephrotoxicity.
    Lee J; Kim S
    Curr Drug Metab; 2018; 19(7):577-583. PubMed ID: 29521220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery.
    Caldwell GW; Ritchie DM; Masucci JA; Hageman W; Yan Z
    Curr Top Med Chem; 2001 Nov; 1(5):353-66. PubMed ID: 11899102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. De-risking drug discovery with ADDME -- avoiding drug development mistakes early.
    Tsaioun K; Jacewicz M
    Altern Lab Anim; 2009 Sep; 37 Suppl 1():47-55. PubMed ID: 19807206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microphysiological systems in early stage drug development: Perspectives on current applications and future impact.
    Kopec AK; Yokokawa R; Khan N; Horii I; Finley JE; Bono CP; Donovan C; Roy J; Harney J; Burdick AD; Jessen B; Lu S; Collinge M; Sadeghian RB; Derzi M; Tomlinson L; Burkhardt JE
    J Toxicol Sci; 2021; 46(3):99-114. PubMed ID: 33642521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the utility of the Beta Human Liver Emulation System (BHLES) for CFSAN's regulatory toxicology program.
    Eckstrum K; Striz A; Ferguson M; Zhao Y; Sprando R
    Food Chem Toxicol; 2022 Mar; 161():112828. PubMed ID: 35066125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Organotypic and Microphysiological Human Tissue Models for Drug Discovery and Development-Current State-of-the-Art and Future Perspectives.
    Youhanna S; Kemas AM; Preiss L; Zhou Y; Shen JX; Cakal SD; Paqualini FS; Goparaju SK; Shafagh RZ; Lind JU; Sellgren CM; Lauschke VM
    Pharmacol Rev; 2022 Jan; 74(1):141-206. PubMed ID: 35017176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development.
    Marx U; Akabane T; Andersson TB; Baker E; Beilmann M; Beken S; Brendler-Schwaab S; Cirit M; David R; Dehne EM; Durieux I; Ewart L; Fitzpatrick SC; Frey O; Fuchs F; Griffith LG; Hamilton GA; Hartung T; Hoeng J; Hogberg H; Hughes DJ; Ingber DE; Iskandar A; Kanamori T; Kojima H; Kuehnl J; Leist M; Li B; Loskill P; Mendrick DL; Neumann T; Pallocca G; Rusyn I; Smirnova L; Steger-Hartmann T; Tagle DA; Tonevitsky A; Tsyb S; Trapecar M; Van de Water B; Van den Eijnden-van Raaij J; Vulto P; Watanabe K; Wolf A; Zhou X; Roth A
    ALTEX; 2020; 37(3):365-394. PubMed ID: 32113184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive assessment of ADMET risks in drug discovery.
    Wang J
    Curr Pharm Des; 2009; 15(19):2195-219. PubMed ID: 19601823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A cocktail of metabolic probes demonstrates the relevance of primary human hepatocyte cultures in a microfluidic biochip for pharmaceutical drug screening.
    Prot JM; Videau O; Brochot C; Legallais C; Bénech H; Leclerc E
    Int J Pharm; 2011 Apr; 408(1-2):67-75. PubMed ID: 21295126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro screening techniques for reactive metabolites for minimizing bioactivation potential in drug discovery.
    Prakash C; Sharma R; Gleave M; Nedderman A
    Curr Drug Metab; 2008 Nov; 9(9):952-64. PubMed ID: 18991592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Developing microphysiological systems for use as regulatory tools--challenges and opportunities.
    Andersen ME; Betts K; Dragan Y; Fitzpatrick S; Goodman JL; Hartung T; Himmelfarb J; Ingber DE; Jacobs A; Kavlock R; Kolaja K; Stevens JL; Tagle D; Lansing Taylor D; Throckmorton D
    ALTEX; 2014; 31(3):364-7. PubMed ID: 25061900
    [No Abstract]   [Full Text] [Related]  

  • 32. Microfluidic cell culture systems for drug research.
    Wu MH; Huang SB; Lee GB
    Lab Chip; 2010 Apr; 10(8):939-56. PubMed ID: 20358102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Introduction to a manuscript series on the characterization and use of microphysiological systems (MPS) in pharmaceutical safety and ADME applications.
    Fabre K; Berridge B; Proctor WR; Ralston S; Will Y; Baran SW; Yoder G; Van Vleet TR
    Lab Chip; 2020 Mar; 20(6):1049-1057. PubMed ID: 32073020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Organotypic and Microphysiological Models of Liver, Gut, and Kidney for Studies of Drug Metabolism, Pharmacokinetics, and Toxicity.
    Shen JX; Youhanna S; Zandi Shafagh R; Kele J; Lauschke VM
    Chem Res Toxicol; 2020 Jan; 33(1):38-60. PubMed ID: 31576743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of body-on-a-chip devices in drug and toxicity studies.
    Esch MB; King TL; Shuler ML
    Annu Rev Biomed Eng; 2011 Aug; 13():55-72. PubMed ID: 21513459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular medicine. NIH dives into drug discovery.
    Couzin J
    Science; 2003 Oct; 302(5643):218-21. PubMed ID: 14551416
    [No Abstract]   [Full Text] [Related]  

  • 37. Microphysiological lung models to evaluate the safety of new pharmaceutical modalities: a biopharmaceutical perspective.
    Ainslie GR; Davis M; Ewart L; Lieberman LA; Rowlands DJ; Thorley AJ; Yoder G; Ryan AM
    Lab Chip; 2019 Sep; 19(19):3152-3161. PubMed ID: 31469131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Collaborative pre-competitive preclinical drug discovery with academics and pharma/biotech partners at Sanford|Burnham: infrastructure, capabilities & operational models.
    Chung TD
    Comb Chem High Throughput Screen; 2014 Mar; 17(3):272-89. PubMed ID: 24409951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug metabolites in safety testing.
    Hastings KL; El-Hage J; Jacobs A; Leighton J; Morse D; Osterberg RE
    Toxicol Appl Pharmacol; 2003 Jul; 190(1):91-2;author reply 93-4. PubMed ID: 12831788
    [No Abstract]   [Full Text] [Related]  

  • 40. Characterization of rat or human hepatocytes cultured in microphysiological systems (MPS) to identify hepatotoxicity.
    Chang SY; Voellinger JL; Van Ness KP; Chapron B; Shaffer RM; Neumann T; White CC; Kavanagh TJ; Kelly EJ; Eaton DL
    Toxicol In Vitro; 2017 Apr; 40():170-183. PubMed ID: 28089783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.